Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 1/20 | 0.51 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 4/20 | 0.51 |
| ▸ | PDE2A | O00408 | 3/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.48 |
| ▸ | ALDH2 | P05091 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.45 |
| ▸ | ACSL6 | Q9UKU0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19358277 | 0.95 | TRIM24 (0.53) | ALBTRIM24TYRTRIM33PPARA | |
| SCHEMBL19358250 | 0.85 | HPGD (0.46) | ALBTRIM24TYRTRIM33PDE2A | |
| SCHEMBL7072470 | 0.85 | TRIM24 (0.55) | ALBTRIM24TYRTRIM33PDE2A | |
| SCHEMBL19358317 | 0.84 | L3MBTL1 (0.58) | PPARAPOLBMAPT | |
| SCHEMBL7164858 | 0.82 | ALDH2 (0.50) | TRIM24TYRTRIM33PDE3BPDE3A | |
| SCHEMBL19358286 | 0.82 | TYR (0.51) | ALBTRIM24TYRTRIM33MAOB | |
| SCHEMBL19358288 | 0.82 | TYR (0.51) | ALBTRIM24TYRTRIM33POLB | |
| SCHEMBL20339391 | 0.82 | TYR (0.63) | TRIM24TYRTRIM33MAOBPOLB | |
| SCHEMBL16873694 | 0.82 | TYR (0.54) | TRIM24TYRTRIM33ALDH2MAOA | |
| SCHEMBL7323609 | 0.82 | TRIM24 (0.58) | TRIM24TYRTRIM33POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-20050158370-A1 | Charge-balanced chemoselective linkers | AMURA THERAPEUTICS LIMITED (GB) | 2005-07-21 | — | — | US | disclosed |
| EP-1493030-A2 | CHARGE-BALANCED CHEMOSELECTIVE LINKERS | Amura Therapeutics Limited (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003087824-A2 | CHARGE-BALANCED CHEMOSELECTIVE LINKERS | AMURA THERAPEUTICS LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
| US-6566494-B1 | Solid support for use in the generation of preferential peptides | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2003-05-20 | — | — | US | disclosed |
| EP-0975662-A1 | HEPATITIS C NS3 PROTEASE INHIBITORS | PEPTIDE THERAPEUTICS LIMITED (GB) | 2000-02-02 | — | — | EP | disclosed |
| US-5917015-A | Support material for solid phase organic synthesis | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1999-06-29 | — | — | US | disclosed |
| WO-1998046630-A1 | HEPATITIS C NS3 PROTEASE INHIBITORS | PEPTIDE THERAPEUTICS LIMITED (GB) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050158370-A1 | Charge-balanced chemoselective linkers | CCR8, CCR10, C1R | ALB 839/4885TRIM24 2252/4885TYR 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.